Sarcomas in Adolescents and Young Adults

PURPOSE OF REVIEW: This review aims to assess the current state of bone and soft tissue sarcomas (STS) management in the adolescent and young adult population (AYA) with a focus on Ewing sarcoma (EWS), osteosarcoma (OS), rhabdomyosarcoma (RMS), and non-rhabdomyosarcoma soft tissue sarcoma (NRSTS). RECENT FINDINGS: There has been a significant growth in novel agents available for bone sarcomas in the AYA population; trials continue to study the efficacy of these agents. The future of STS will likely include more single histology and targeted biologic studies. Joint pediatric and adult sarcoma clinical trials are feasible. AYAs continue to represent an underserved patient population in medical oncology. Collaboration between pediatric and adult practices may increase patient enrollment and enable single histology and biology specific studies. Trials for EWS, OS, RMS, and NRSTS should include both pediatric and adult patients whenever possible.